Business
DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency
DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sal...
About this update from Dri Healthcare Trust
[{"type":"text","content":"\n \n \n \n DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n – Transaction pushes total committed capital to over\n \n US$1 billion\n \n since IPO –\n \n \n \n \n – Second Xenpozyme royalty increases exposure to rare diseases –\n \n \n \n \n – Long-term asset further increases portfolio duration –\n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n July 2, 2024\n \n \n /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the \"Trust\"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a second royalty interest in the worldwide net sales of Xenpozyme (olipudase alfa) from HLS Therapeutics Inc. (\"HLS\") for an aggregate purchase price of up to\n \n US$45.75 million\n \n , comprised of a\n \n US$13.25 million\n \n upfront payment and up to\n \n US$32.5 million\n \n in performance-based outbound milestone payments.\n \n \n \n \n \n \n \n \n \n Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (\"ASMD\"), also known as Niemann-Pick disease, in pediatric and adult patients. Xenpozyme was approved in\n \n Japan\n \n in\n \n March 2022\n \n , by the European Commission in\n \n June 2022\n \n , and by the U.S. Food and Drug Administration in\n \n August 2022\n \n . There are no other products currently known to be in late-stage development for the treatment of ASMD. Xenpozyme is marketed worldwide by Sanofi S.A. (\"Sanofi\").\n \n \n \"Xenpozyme is an important treatment that materially increases the quality of life of patients suffering from ASMD,\" said\n \n Behzad Khosrowshahi\n \n , the Trust's Chief Executive Officer. \"The drug has performed well since our initial investment in\n \n October 2022\n \n , and we ...